Very well written regarding the recent affairs.
As long as partial halt for additional patient screening is concerned, it may have nothing to do with the screening per se in the first place; otherwise it would be solved in due time.
Just want to add to your excellent summary:
Public traded companies, big or small, do those independent internal investigations into their own affairs all the time, due to either internal or external pressure.
Almost all would not report the findings publicly and instead they would make appropriate (correct) actions either due to the requirements of compliance or otherwise.
In the case of nwbo, I think the process is still on going, but the company has actually revealed some investigating results via SEC filing:
1) the company has hired additional personnel to improve on its financial affairs reporting, including 10Q, 10K, etc, to further separate duties from LP in this front;
2) Yes, the MFN clause has been removed to align LP's interests with those of investors;
3) the company has hired additional independent directors to strength the board;
4) the company has paid off all its money owing to Four M in accordance with their patent-in-trust agreement so now the company is in full control of its patent portfolio.
As a matter of fact, all the outstanding issues detected by auditors have been all solved except one item (what specifically I don't recall at this time).
So the company has moved forward positively toward a company with good governance.
I guess if LP has no confidence in the future of the company, it would be no reason for she to have implemented the above.
Yes, the company has strongly suggested the L trial has been moving toward completion for months now since Q2 report. It is a strong possibility that the results of L trial may be available in the near future.
Market Data 
Markets 
AI
